作者: Anouar Hafiane , Jacques Genest
DOI: 10.1016/J.BBACLI.2015.01.005
关键词: Lipoprotein 、 Potential biomarkers 、 Biomarker (cell) 、 Bioinformatics 、 Lipoproteins measurement 、 High-density lipoprotein 、 PON1 、 Clinical trial 、 Cholesterol 、 Medicine
摘要: Plasma high density lipoprotein cholesterol (HDL) comprises a heterogeneous family of species, differing in surface charge, size and lipid protein compositions. While HDL (C) mass is strong, graded coherent biomarker cardiovascular risk, genetic clinical trial data suggest that the simple measurement HDL-C may not be causal preventing atherosclerosis nor reflect functionality. Indeed, health. To assess issue function as potential therapeutic target, robust analytical methods are required. The complex pleiotropic effects make development single challenging. Development laboratory assays accurately must developed validated brought to high-throughput for purposes. This review discusses limitations current technologies separate quantify application predict CVD, with an emphasis on emergent approaches biomarkers practice.